Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2018; 18(4):282-287
DOI: 10.5428/pcar20180413
Efficacy of high-dose statins administration before surgery on the reduction of cardiovascular events: a meta analysis
1. CAO AiLin(Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, China 601905411@qq.com)
2. QIAN Jiao(Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, China )
3. WANG Zhuo(Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai 200433, China wangzhuo088@163.com)
ABSTRACT  Objective: To evaluate systematically the therapeutic efficacy of short-term high-dose statins administration before surgery in Asian population with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention(PCI) on reducing the incidence of major adverse cardiac events(MACE). Methods: Published randomized controlled trials(RCTs) were retrieved from PubMed, EMBase and Cochrane Library. Two reviewers independently screened studies according to the exclusion and inclusion criteria and data were extracted. Then,quality evaluation was made by using Cochrane manual 5.1.0. Meta analysis was performed by using Rev Man 5.3 software. Results: A total of 7 RCTs were included,involving 1381 statin-nave Asian patients. Of the 1381 patients,689 patients were given high-dose statins before PCI (the observation group),and 692 patients were given normal or low-dose statins or no drugs before PCI (the control group).The results of meta analysis showed that the incidence of MACE in the observation group was significantly lower than that in the control group,with statistical significance (P<0.01),and that high dosage of statins before PCI had impact on the incidence of percutaneous myocardial infarction (PMI) in perioperative patients.The incidence of PMI in the observation group was significantly lower than that in the control group,also with statistical significance (P<0.01).Conclusion:In Asian patients with acute coronary syndrome, high-dose statins administered before PCI could significantly reduce the incidence of MACE and PMI within 30 days after surgery.
Welcome to PCAR! You are the number 175 reader of this article!
Please cite this article as:
CAO AiLin,QIAN Jiao,WANG Zhuo,. Efficacy of high-dose statins administration before surgery on the reduction of cardiovascular events: a meta analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(4): 282-287.
References:
1. Interventional Cardiology Group of Cardiovascular Branch of Chinese Medical Association;Specialized Committee of Thrombosis Prevention and Treatment of Cardiovascular Physicians Branch, Chinese Medical Doctor Association;Editorial Committee of Chinese Journal of Cardiology. Guidelines for percutaneous coronary intervention in China(2016)[J]. Chin J Cardiol,2016,44(5):382-400. In Chinese.
2. Cardiovascular Branch of Chinese Medical Association, Editorial Committee of Chinese Journal of Cardiology. Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes(2016)[J]. Chin J Cardiol,2017,45(5):359-376. In Chinese.
3. Cardiovascular Branch of Chinese Medical Association, Editorial Committee of Chinese Journal of Cardiology. Guidelines for the diagnosis and treatment of acute ST segment elevation myocardial infarction[J]. Chin J Cardiol, 2015,43(5):380-393. In Chinese.
4. Nomoto K, Watanabe I, Oba T, et al. Safety and efficacy of sirolimus-eluting stent in patients with acute coronary syndrome undergoing emergency procedures[J]. Circ J,2008,72(7):1054-1058.
5. BAI Jin, ZU LingYun,ZHANG YongZhen,et al. Efficacy of high-dose statins pretreatment on PCI-related inflammation and myocardial injury[J]. Chin J Front Med(Elect Version), 2011,3(5):36-41. In Chinese with English abstract.
6. Rosenson R S, Tangney C C, Casey L C.Inhibition of proinflammatory cytokine production by pravastatin[J].Lancet, 1999,353(9157):983-984.
7. Mason J C, Ahmed Z, Mankoff R, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury[J]. Circ Res,2002,91(8):696-703.
8. Yokoyama S, Ikeda H, Haramaki N, et al. HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats[J]. J Cardiovasc Pharmacol,2005,45(4):375-381.
9. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial[J]. J Am Coll Cardiol,2007,49(12):1272-1278.
10. ZHANG Feng,DONG LiLi, GE JunBo. Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention:a meta-analysis[J]. Ann Med, 2010,42:171-177.
11. LIU YangChun, SU Qiang, LI Lang. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials[J]. Clin Cardiol, 2013, 36(12):E41-E48.
12. WANG Le, PENG PingAn, ZHAO Ou, et al. High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention:a meta-analysis of twenty-four randomized controlled trials[J]. PLoS One,2014,9(12):e113352.
13. HUO Yong, GE JunBo, Han YaLing, et al. Expert consensus on intensive statins therapy in patients with acute coronary syndrome[J]. Chin J Intervent Cardiol,2014,22(1):4-6. In Chinese.
14. Jang Y S, ZHU JunRen, Ge JunBo, et al. Preloading with atorvastatin before percutaneous coronary intervention in statin-nave Asian patients with non-ST elevation acute coronary syndromes:A randomized study[J]. J Cardiol,2014,63(5):335-343.
15. ZHENG Bo, JIANG Jie, LIU HuiLiang, et al. Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention: results of the ISCAP (intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention) randomized controlled trial[J]. Eur Heart J Suppl, 2015,17(Suppl B):B47-B56.
16. Stong N J, Robinson J G, Lichtenstein A H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25):2889-2934.
17. Higgins J P T, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[EB/OL]. (2011-03)[2017-10]. http://handbook-5-1.cochrane.org/.
18. Kim J S, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction:the statin STEMI trial[J]. JACC Cardiovasc Interv,2010,3(3):332-339.
19. LUO Jun, LI Jiang, SHEN XiangQian,et al. The effects and mechanisms of high loading dose rosuvastatin therapy before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol,2013,167(5):2350-2353.
20. WANG XueZhong, WANG YueSong, WANG ShaoJun, et al. The effects of 80 mg loading dose atorvastatin pretreatment on myocardial protection during percutaneous coronary intervention in elderly patients with non-ST-segment elevation acute coronary syndrome[J]. Heart,2012,98(Suppl 2):E1-E319.
21. WANG ZhengZhang, DAI HongYan, XING MingQing, et al. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes[J]. J Cardiovasc Pharmacol Ther, 2013,18(4):327-333.
22. YU XingLong, ZHANG HaiJuan, REN ShaoDa, et al. Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury[J]. Coron Artery Dis, 2011, 22(2):87-91.
23. Yun K H, Jeong M H, Oh S K,et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int J Cardiol, 2009,137(3):246-251.
24. Sciascio D G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE (atorvastatin for reduction of myocardial damage during angioplasty) randomized trial[J]. J Am Coll Cardiol,2009,54(6):558-565.
25. Briguori C, Visconti G, Focaccio A,et al. Novel approaches for preventing or limiting events (Naples) Ⅱ trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction[J]. J Am Coll Cardiol,2009,54(23):2157-2163.
26. Sardella G, Lucisano L, Mancone M, et al. Comparison of high reloading ROsuvastatin and atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA Ⅱ trial[J].Int J Cardiol,2013,168(4):3715-3720.
27. Roffi M, Patrono C, Collet J P, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(3):267-315.
28. ZHANG Ming, LI Xuan, CHEN Hong, et al. Safety of high-dose atorvastatin in Chinese patients:a meta-analysis[J].Chin J Intervent Cardiol, 2016,24(2):88-95.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口